Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma

Rubello, Domenico; Wong, Ka Kit; Marzola, Maria Cristina; Beheshti, Mohsen; Ambrosini, Valentina; Chondrogiannis, Sotirios; Gross, Milton D.

doi:10.1007/s00259-011-2035-2

Cited by 2 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, in spite of an increasing volume of evidence available in the literature on the usefulness of PET/CT with different radiopharmaceuticals in recurrent MTC [5][6][7][8][9][10][11][12][13]16], the 2015 revised ATA MTC guidelines appear to consciously marginalise the role of Nuclear Medicine in this setting, thereby ignoring the emerging role of functional information obtained from highly selective uptake of radiopharmaceuticals in the MTC tissue. As far as the role of Nuclear Medicine is concerned in this rare tumour entity, compared to previous iteration of these ATA guidelines, the 2015 ATA guidelines on MTC management seem to represent a reversal rather than an advance, even though the body of scientific evidence in the literature has grown considerably since the publication of 2009 ATA MTC guidelines.…”

Section: B)mentioning

confidence: 99%

See 1 more Smart Citation

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

Treglia

Aktolun²,

Chiti

et al. 2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

In 2007, the American Thyroid Association (ATA) assembled a group of expert clinicians and basic scientists to evaluate published papers and to develop evidence-based guidelines for the diagnosis and management of patients with medullary thyroid carcinoma (MTC). The first ATA guidelines on the management of patients with MTC were published in 2009 [1]. In 2015, ATA released the first revised version of these guidelines [2], in order to assist clinicians of all specialties in the management of these patients.The ATA Board of Directors selected the Task Force members for elaborating these revised guidelines based on published scientific data in the management of MTC, and included international scientists from the fields of endocrinology, ethics, genetics, medical oncology, molecular biology, nuclear medicine, pathology, paediatrics, radiation oncology, and surgery [2]. Task Force members reviewed relevant articles on MTC by searching MEDLINE/PubMed from January 1980 to April 2014 using specific MTC-related search terms. Task Force members also provided additional relevant articles, book chapters, and other materials. Recommendations were graded using criteria adapted from the United States Preventive Services Task Force Agency for Healthcare Research and Quality as were used in the previous MTC guidelines [1,2]. After revisions and critical reviews of a series of drafts, the Task Force developed a final document, and the ATA Board of Directors approved the revised set of guidelines [2].Compared to the earlier version [1], the 2015 revised ATA guidelines on the management of patients with MTC (now consisting of 67 recommendations and related explanatory * Giorgio Treglia giorgiomednuc@libero.it on behalf of the EANM and the EANM Thyroid Committee

show abstract

Section: B)mentioning

confidence: 99%

“…In fact, whereas the role of nuclear medicine techniques in preoperative staging of MTC seems limited, on the other hand, an extensive body of evidence in literature clearly supports the role of PET/CT using different radiopharmaceuticals, F-DOPA in particular, in detecting persistent/recurrent MTC [5][6][7][8][9][10][11][12].…”

mentioning

confidence: 99%

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

Treglia

Aktolun²,

Chiti

et al. 2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Several studies [8,9] and a meta-analysis on 18F-DOPA PET revealed a detection rate of 66% (per patient) and 71% (per lesion) [10], which represents, at present, the best values achievable.…”

mentioning

confidence: 99%

SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

Maffione

Giammarile

Rubello

2017

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma

Cited by 2 publications

References 47 publications

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

Contact Info

Product

Resources

About